Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296391 | 0.87 | CYP3A4 (0.67) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL29520218 | 0.87 | CYP3A4 (0.67) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL28197163 | 0.82 | CYP3A4 (0.60) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL22111494 | 0.74 | CYP3A4 (0.56) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL11878306 | 0.74 | CYP3A4 (0.56) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL7158060 | 0.73 | CYP3A4 (0.60) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL49899 | 0.73 | TDP1 (0.70) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL14606239 | 0.73 | CYP3A4 (0.60) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL9630369 | 0.73 | CYP3A4 (0.55) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL1169221 | 0.73 | CYP3A4 (0.60) | CYP3A4TRPA1TDP1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240181009-A1 | SYNTHEKINE COMPOSITIONS AND METHODS OF USE | HOWARD HUGHES MEDICAL INSTITUTE | 2024-06-06 | — | — | US | disclosed |
| US-11993645-B2 | Compositions comprising R-Spondin (RSPO) surrogate molecules | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-05-28 | — | — | US | disclosed |
| EP-3515476-B1 | FUSION COMPRISING A CELL PENETRATING PEPTIDE, A MULTIEPITOPE AND A TLR PEPTIDE AGONIST FOR TREATMENT OF CANCER | AMAL THERAPEUTICS SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024091979-A1 | CD276 (B7-H3) ANTIBODY-DRUG CONJUGATES | BRICKBIO, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11958891-B2 | Tissue-specific Wnt signal enhancing molecules and uses thereof | Surrozen Operating, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2024064233-A1 | NEAR-INFRARED IMAGING AGENT AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024049543-A1 | COMPOSITIONS AND METHODS FOR TRANSGLUTAMINASE-MEDIATED ENDOCYTOSIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-3757134-B1 | CHLORIDE SALT OF TAT-NR2B9C | NONO INC (CA) | 2024-03-06 | — | — | EP | disclosed |
| US-11911438-B2 | Chloride salt of TAT-NR2B9C | NONO INC. (CA) | 2024-02-27 | — | — | US | disclosed |
| WO-2024040118-A2 | CELL TARGETING MULTICOMPONENT POLYPEPTIDE | Surrozen Operating, Inc. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-5256413-A | Administering a conjugate consisting of monoclonal antibody coupling to tissue plasminogen activator | THE GENERAL HOSPITAL CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
| WO-1992018139-A1 | CHIMERIC MOLECULE WITH PLASMINOGEN ACTIVATOR ACTIVITY AND AFFINITY FOR ATHEROSCLEROTIC PLAQUES | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0506884-A1 | METHOD OF DELIVERING MOLECULES INTO EUKARYOTIC CELLS. | WHITEHEAD BIOMEDICAL INST (US) | 1992-10-07 | — | — | EP | disclosed |
| US-5116613-A | Antibody-thrombolytic agent product and method of use | THE GENERAL HOSPITAL CORPORATION (US) | 1992-05-26 | — | — | US | disclosed |
| EP-0465556-A1 | PLATELET SPECIFIC IMMUNOCONJUGATES. | CENTOCOR INC (US) | 1992-01-15 | — | — | EP | disclosed |
| WO-1991009958-A2 | METHOD OF DELIVERING MOLECULES INTO EUKARYOTIC CELLS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 1991-07-11 | — | — | WO | disclosed |
| WO-1990011783-A1 | PLATELET SPECIFIC IMMUNOCONJUGATES | CENTOCOR, INC. (US) | 1990-10-18 | — | — | WO | disclosed |
| US-4916070-A | Fibrin-specific antibodies and method of screening for the antibodies | THE GENERAL HOSPITAL CORPORATION (US) | 1990-04-10 | — | — | US | disclosed |
| WO-1987006263-A1 | FIBRIN-SPECIFIC ANTIBODIES AND METHOD OF SCREENING FOR THE ANTIBODIES | THE GENERAL HOSPITAL CORPORATION (US) | 1987-10-22 | — | — | WO | disclosed |
| EP-0187658-A2 | Method and use for site-specific activation of substances | THE GENERAL HOSPITAL CORPORATION (US) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911438-B2 | Chloride salt of TAT-NR2B9C | CHRNA9, SCN9A, GRIN2C | CYP3A4 4681/4885TRPA1 380/4885TDP1 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.